51
Participants
Start Date
October 11, 2016
Primary Completion Date
July 5, 2018
Study Completion Date
July 5, 2018
Olaratumab
Administered IV
Doxorubicin
Administered IV
External Beam Radiotherapy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milan
Levine Children's Hospital, Charlotte
Moffitt Cancer Center & Research Inst, Tampa
All Children's Hospital, St. Petersburg
Vanderbilt University Medical Center, Nashville
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville
Washington University Medical Center, St Louis
Kansas City Cancer Center, Overland Park
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon
Mary Crowley Cancer Research, Dallas
USC/Norris Comp Cancer Center, Los Angeles
Yale University School of Medicine, New Haven
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London
Eli Lilly and Company
INDUSTRY